vimarsana.com

Latest Breaking News On - Ted human effector - Page 2 : vimarsana.com

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for

United statesFrance generalUnited kingdomAssia mouhoutKostenloser wertpapierhandelAndreas wallnoeferBayern kapitalPhil lhuillierMarion bougeardTrophic communicationsNovartis venture fundJeito capitalBrandon capitalVesalius biocapitalBiogeneration venturesGrowth differentiation

CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors

CatalYmtoday announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation

United statesFrance generalUnited kingdomBayern kapitalSue charlesCiara byrneCatalym gmbKostenloser wertpapierhandelAndreas wallnoeferJonathan tobinPhil lhuillierMana communicationsTrophic communicationsNovartis venture fundBrandon capitalJeito capital

CatalYm GmbH: CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

In an oral presentation at ESMO 2022, data from the GDFATHER-1 trial showed that treatment with visugromab and the anti-PD-1 inhibitor nivolumab resulted in excellent tolerability and significant anti-tumor

France generalKostenloser wertpapierhandelCatalym gmbIgnacio melero bermejoPhil lhuillierPhil lhuilierInternational coordinating investigator profTrophic communicationsEuropean society for medical oncologyEuropean societyMedical oncologyInternational coordinating investigatorUniversidad de navarraEugen leoChief medical officerPhill huillier

CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of

Kostenloser wertpapierhandelCatalym gmbPhil lhuillierIgnacio melero centerWorld health organizationInternational nonproprietary nameTrophic communicationsDifferentiation factorTed human effectorIgnacio meleroAdvanced medical researchPrincipal investigatorEugen leoChief medical officerPhill huillierGrowth differentiation

vimarsana © 2020. All Rights Reserved.